Secukinumab receives expanded approvals in EU for pediatric arthritic conditions
July 5th 2022The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.